- Home
- ELVN vs LKFT Comparison
ELVN vs LKFT Comparison
Compare ELVN & LKFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | LKFT |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ELVN | LKFT |
|---|---|---|
| Price | $53.59 | $29.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 134.6K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $28.00 |
| 52 Week High | $53.89 | $30.91 |
Technical Indicators
Market Signals| Indicator | ELVN | LKFT |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 59.93 |
| Support Level | $25.63 | $29.36 |
| Resistance Level | N/A | $30.91 |
| Average True Range (ATR) | 2.56 | 0.50 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 95.86 | 40.23 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About LKFT Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.